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doi:10.1016/j.ejvs.2009.11.020Abstract Treatment of carotid artery stenosis by endarterectomy or stenting can significantly
reduce stroke risk. In clinical practice, indication for surgery or stenting is primarily based on the
degree of stenosis, but there is growing awareness that pathophysiological features within
a vulnerable plaque play a key role in predicting stroke risk. Important molecular processes asso-
ciated with plaque vulnerability are inflammation, lipid accumulation, proteolysis, apoptosis,
angiogenesis and thrombosis. The rapidly emerging field of molecular and functional imaging
strategies allows identification of pathophysiological processes in carotid artery stenosis.
We aimed to review the literature regarding the current most promising advanced imaging
techniques in carotid artery disease.
Various advanced imaging methods are available, such as high-resolution magnetic resonance
imaging (HR-MRI), single photon emission computed tomography (SPECT), positron emission
tomography (PET) and near-infrared fluorescence (NIRF). Radionuclide and fluorescent tracers
that identify inflammation, apoptosis and proteolysis, such as FDG, MMP probes and Annexin
A5, are promising. A combination of activity of molecular processes and detailed anatomic infor-
mation can be obtained, providing a powerful tool in the identification of the vulnerable plaque.
With these developments, we are entering a new era of imaging techniques in the selection of
patients for carotid surgery.
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Table 1 Search results.
Search terms Results
1. ‘‘Carotid plaque’’ AND imaging 226
2. #1 AND inflammation 18
3. #1 AND lipids 74
4. #1 AND angiogenesis 4
5. #1 AND PET 9
6. #1 AND MRI 117
7. #1 AND SPECT 4
8. Atherosclerosis AND NIRF 7
9. Atherosclerosis AND PET 167
10. Atherosclerosis AND SPECT 163
11. Atherosclerosis AND HR-MRI 2
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Stroke is the third leading cause of death after ischaemic
heart disease and cancer.1 About 80% of all strokes are
ischaemic and approximately 25e50% of these are caused
by an unstable carotid artery plaque.2 However, not all
plaques become symptomatic and result in a stroke or
a transient ischaemic attack (TIA). Treatment of carotid
artery stenosis by surgical endarterectomy or stenting can
significantly reduce stroke risk. On the other hand, about
3e9% of patients undergoing interventional treatment are
expected to suffer stroke or death as a complication from
such a treatment, with stenting having a higher risk for
major complications than carotid endarterectomy.3
Current selection criteria for intervention are predomi-
nantly determined by the grade of stenosis and symptom-
atology. It is generally accepted to be more aggressive in
a high-grade symptomatic carotid stenosis, but invasive
interventions in lower-grade stenosis are still a matter of
debate. Further, there is growing awareness that stenosis
severity alone has limited value in predicting plaque
stability and various molecular processes have, indepen-
dently of degree of stenosis, shown to be importantly
associated with plaque vulnerability.
Current imaging of carotid artery stenosis
Traditional imaging methods of carotid artery disease
include angiography, duplex ultrasound and computed
tomography angiography (CTA). These methods mainly
focus on anatomic features of the plaque; however, some
techniques are also able to detect morphologic character-
istics of plaque vulnerability such as ulceration, a large
lipid or necrotic core and a thin fibrous cap.
Angiography was the gold standard in the North Amer-
ican Symptomatic Carotid Endarterectomy Trial and Euro-
pean Carotid Surgery Trial to determine degree of stenosis.
Duplex ultrasonography and CTA are also being used to
determine the degree of stenosis in carotid artery disease.
With regard to plaque morphology, several studies have
compared the imaging results to histopathological findings
as the gold standard. Angiography was able to detect
ulceration with a sensitivity and specificity of approxi-
mately 45% and 75%, respectively.4,5 Calcification and
ulceration could be determined by ultrasound grey-scale
appearance. Computer-assisted duplex ultrasound image
analyses by using grey-scale median (GSM) showed corre-
lations between GSM values and histopathological findings
varying from 46%6 to 75%.7
CTA has also shown to identify plaque ulceration,
calcification and lipid cores with an overall agreement of
about 75% between CTA findings and histology.8,9
Among the current clinically available imaging modali-
ties, MRI seems the most accurate method to image plaque
morphology in carotid artery disease. High-resolution MRI
(HR-MRI) can detect differences in morphologic plaque
characteristics between symptomatic and asymptomatic
carotid plaques. U-King-Im et al. prospectively evaluated
differences in carotid plaque characteristics in 20 symp-
tomatic and 20 asymptomatic patients using HR-MRI.
Symptomatic patients were more likely to have a thinfibrous cap, intra-plaque haemorrhage, a large lipid core
and a complex morphology.10 In another group of 60
patients, HR-MRI was able to detect fibrous cap thickness,
intra-plaque haemorrhage, and other components associ-
ated with an increased risk of thrombo-embolic events.11
Future imaging of carotid artery stenosis
Although limited morphological plaque features may be
detected by current imaging methods, information about
molecular processes is only available at postoperative or
post-mortem examination of the plaque. There is growing
awareness that molecular processes such as inflammation,
lipid accumulation, proteolysis, apoptosis, angiogenesis
and thrombosis are highly related with plaque vulnerability.
In vivo identification of these processes would be of great
advantage in the selection for vascular intervention.
New techniques have been developed to image cellular
and molecular processes and provide biological and path-
ological information regarding the plaque. These advanced
molecular imaging methods may play a central role in
determination of the unstable plaque and also provide
a powerful tool for selection of individual therapeutic
strategies and monitoring the effect of interventions.
In this review, we aim to summarise innovative func-
tional imaging methods in carotid artery disease. In the
next part, we discuss the processes and related cellular and
molecular targets associated with plaque instability and the
corresponding advanced imaging methods.
Search strategy
A Medline search from January 1966 to August 2009 was
carried out to identify publications reporting experience
with innovative functional imaging techniques in athero-
sclerotic disease, and carotid stenotic disease in particular.
Search terms used were ‘atherosclerosis’, ‘plaque’,
‘carotid’, ‘imaging’, ‘magnetic resonance imaging’, ‘posi-
tron emission tomography’, ‘single photon emission
computed tomography’, ‘near-infrared fluorescence’,
‘inflammation’, ‘lipid accumulation’, ‘proteolysis’, ‘angio-
genesis’ and ‘apoptosis’, in various combinations with the
Boolean operators AND, OR and NOT (Table 1). Only
Figure 1 Coronal view of a 50e70% symptomatic stenosis of
the internal carotid artery on the left side in a 77-year-old
male patient as shown by FDG-PET-CT imaging. No FDG uptake
was noted at the level of the asymptomatic stenosis of the
internal carotid artery on the contralateral side.
Advanced Carotid Plaque Imaging 127publications in English language were included. Manual
cross-referencing was also performed. The final reference
list was selected on the basis of relevance to the topics in
this review article.
Functional carotid plaque imaging
Inflammation
Inflammation plays a key role in early atherosclerotic lesions
and in atherosclerotic plaque destabilisation. Especially,
macrophages play a central role in plaque pathogenesis. By
ingesting lipids, they transform into foam cells and produce
a large array of pro- and anti-inflammatory cytokines. The
highly inflammatory vulnerable plaque is typified by an
abundance of inflammatory cells and proteins that are all
potential targets for molecular imaging tracers. Therefore,
molecular imaging of inflammatory activity in the plaque
may predict vulnerability and stroke risk.
The most widely studied imaging method to identify
inflammatory processes in carotid artery plaques is radio-
nuclide scintigraphic imaging by positron emission tomog-
raphy (PET). Radionuclide tracers for macrophage
metabolism, macrophage recruitment and inflammatory
markers have also been developed and have potential to
image inflammatory activity.12 18Fluorodeoxyglucose (FDG)
is a glucose analogue that is taken up by glucose-using cells
and accumulates in proportion to metabolic activity. FDG-
PET has extensively been used in cancer patients. Some
cancer patients undergoing FDG-PET showed uptake of FDG
in the large arteries and they were retrospectively identified
as having risk factors for atherosclerosis.13 This suggested
that atherosclerotic plaques may be suitable for FDG-PET
imaging. In atherosclerosis, FDG-PET is thought to identify
only those plaques that are most actively inflamed and at
highest risk for instability and is a potential method for non-
invasive identification of an unstable carotid plaque (Fig. 1).
The first clinical study using FDG-PET in carotid artery
plaques was performed in 2002, showing more accumula-
tion of FDG in unstable plaques.14 FDG-PET signals have also
shown to correlate with histological macrophage staining or
macrophage markers in human atherosclerotic plaques.15,16
In another clinical study, 12 patients with a recent TIA
underwent FDG-PET and high-resolution MRI. FDG uptake
was high in 83% of patients with lesions that were
compatible with the patients’ presenting symptoms.17
FDG uptake within an arterial wall or plaque can be
quantified in several ways, but there is always a partial
volume error (PVE), depending on the spatial resolution of
the imaging technique that is being used.18 PET has an
advantage over SPECT in having a 2e3 times better spatial
resolution.19 Izquierdo-Garcia et al.20 recently studied the
reproducibility of methods of quantification by MR-guided
FDG-PET in symptomatic carotid artery plaques and
compared quantification methods to a gold standard tech-
nique using the Patlak analysis.21 MR-guided FDG-PET
showed to be a highly reproducible technique.
Another radionuclide tracer that has been used in
carotid artery patients is 99mTechnetium-Interleukin-2
(99mTc-IL-2). Annovazzi et al. showed that in human carotid
artery disease there is 99mTc-IL-2 uptake correspondingwith histological findings of IL-2-receptor positive cells.
However, there was no correlation between 99mTc-IL-2
uptake and ultrasound classification by means of echos-
tructure or luminal surface aspects.22 Other promising
radionuclide tracers used to image inflammation in
atherosclerosis are 125I-monocyte chemotactic protein-1
(125I-MCP-1)23 and 131amino malonic acid monoclonal anti-
body (131AMA-MoAB)24 but they have not been studied in
vivo yet. Therefore, of all radionuclide tracers, 18FDG has
currently the most clinical potential to identify inflamed
plaques in patients with carotid artery disease.
In addition to radionuclide tracers, a variety of magnetic
nanoparticles (MNPs) have been developed to detect
aspects of inflammation in the atherosclerotic plaque.
Nanoparticles are digested by macrophages and accumu-
late in macrophages that are present in the carotid artery
plaque. MNPs are detectable in vivo by high-resolution MRI
as explained earlier or, as in case of fluorescent MNPs, by
near-infrared fluorescence (NIRF). For example, the
inflammatory molecule vascular cell adhesion molecule-1
(VCAM-1). VCAM-1 expression could be imaged in vivo in
a murine model of atherosclerosis with MRI and fluores-
cence imaging using multimodal nanoparticles (NPs).25 In
humans, VCAM-1 could potentially be detected by MRI and
NIRF non-invasively in carotid artery plaques but its value is
unknown.26Lipid accumulation
Lipid accumulation not only plays a role in the initial phases
of atherogenesis, but is also important in the stability of the
atherosclerotic plaque. Unstable lesions have shown to
128 L. Hermus et al.have a much greater area occupied by lipid. In addition,
elevated oxidised low-density lipoprotein (LDL) levels play
a role in the transition from stable to unstable plaques and
are associated with higher risk for atherosclerotic compli-
cations. In carotid artery disease, technetium-99m labelled
LDL (99mTc-LDL) was used for identification of plaque and
appeared to accumulate depending on plaque composi-
tion.27 Another study in carotid artery plaques compared
99mTc-oxLDL uptake between normal carotid arteries and
patients with a carotid artery stenosis. They found signifi-
cantly higher uptake of 99mTc-oxLDL in carotid plaques
compared with normal carotid arteries. However, rela-
tionship between 99mTc-oxLDL uptake and plaque vulnera-
bility by comparison among stable and unstable plaques
was not assessed.28 Although clinical experience in imaging
lipid accumulation is limited, some results suggest that at-
risk plaques with high lipid content may be detected by
non-invasive imaging in the future.Proteolysis
Release of proteolytic enzymes such as matrix metal-
loproteinases (MMPs) and cathepsin cystein proteases
(CCPs) has been suggested as a mechanism of cap erosion
and thus plaque destabilisation. Several studies in athero-
sclerotic plaques have shown proteolytic activity in relation
to plaque instability.29,30 Therefore, non-invasive visual-
isation and quantification of MMP and CCP activity is of
great potential in risk assessment of carotid artery stenosis.Figure 2 Multispectral near-infrared fluorescence imaging within
USA) of a resected left-sided symptomatic >70% carotid stenosis in
infrared fluorescence signal before (autofluorescence, middle) an
probe (MMPSense, VisEn Medical, Boston, MA, USA; right). After
identified both at the intraluminal and extraluminal sides, most pre
of the common carotid bulb. (With kind permission of Niels Harlaa
Groningen, The Netherlands)Radiolabelled molecules designed to specifically target
proteolytic activity have been developed for scintigraphic
techniques such as SPECT and PET. For example, radio-
labelled MMP inhibitors that bind to a broad spectrum of
MMPs have been studied in mice and showed higher uptake
in carotid artery stenosis compared to normal arteries.31
Histological analysis showed co-localisation of the specific
tracer and MMP-9. In rabbits, MMP activity could be
detected by non-invasive SPECT imaging and correlated
well with immunohistochemically verified macrophage
infiltration and presence of MMP-2 and MMP-9 in the
atherosclerotic plaque. In addition, statin therapy and
dietary modification showed to decrease MMP activity as
visualised by SPECT and again immunohistochemical
correlations were high.32 This indicates that SPECT may be
an important tool for monitoring of effect of new therapy
strategies. However, most of the tracers have only been
validated in animal studies and only 111In-DTPA-N-TIMP-2
has been used in humans.33 The development of new
tracers in atherosclerotic plaques is complicated by a so-
called poor target-to-background ratio, which means that
background activity makes it hard to distinguish plaque
uptake from surrounding healthy tissue (Fig. 2).
Another new and promising technique to image proteo-
lytic activity in atherosclerotic plaques is NIRF molecular
imaging. This technique operates in the near-infrared
spectrum of light and uses activatable probes that provide
fluorescent images to detect enzymatic action of proteo-
lytic enzymes such as MMPs and CCPs. Probes, such as
gelatinase-activated probes34 or cathepsin-B-sensitiveIVIS Spectrum camera (Caliper Life Sciences, Hopkinton, MA,
a 74-year-old woman. Ex vivo plaque in white light (left), near-
d after incubation with MMP-sensitive activatable fluorescent
incubation with MMPSense clear hotspots (yellow areas) were
sent in the origin of the internal carotid artery and at the level
r and Johannes de Jong, University Medical Center Groningen,
Advanced Carotid Plaque Imaging 129probes35 are conjugated with NIRF fluorochromes. These
probes produce very low background fluorescence and after
activation produce a profound amplification of fluores-
cence. This way, vulnerable plaques with high proteolytic
activity can be identified e at this stage only ex vivo or in
animal studies. The first NIRF application in human carotid
artery plaques was recently reported by Wallis de Vries
et al. who detected MMP-2 and MMP-9 in a carotid endar-
terectomy specimen (Fig. 2).36 However, it will take tech-
nical developments and preclinical toxicity testing before
in vivo studies in humans can be performed with NIRF.
Furthermore, the reporter capabilities and specific cellular
distribution in vivo needs to be understood and technical
aspects, such as dose-finding studies of a fluorescent tracer
and timing of imaging, need to be improved to obtain
optimal fluorescence signals of a plaque in situ.
Angiogenesis
In atherosclerotic plaques, the formation of microvessels
has been studied as a possible contributing factor to plaque
destabilisation and rupture. Neo-vessels in carotid artery
plaques are fragile and prone to rupture and may cause
plaque growth and intra-plaque haemorrhage, resulting in
a high-risk plaque.37 Several angiogenic cytokines, such as
vascular endothelium growth factor (VEGF), integrins or
angiotensin may be potential targets for molecular imaging
of angiogenesis in plaque formation.38,39 Angiotensin 1
receptor40 and VEGF radionuclide tracers41 have already
been used in other diseases in which angiogenesis plays an
important role, but not in atherosclerosis. For example,Figure 3 Non-invasive radionuclide imaging of proteolytic (MMP
loproteinase inhibitor (MPI) and 111In-labelled Annexin A5 in atheros
(bottom) of atherosclerotic rabbit on uninterrupted high-cholester
display images immediately (0 h) after radiotracer administration, w
vertebral column. The right sets in A and B show target localisation
the atherosclerotic lesions of the abdominal aorta is observed (ar
California, Irvine, USA.)non-invasive imaging of angiogenesis by radionuclide VEGF
tracers42 or fluorescent VEGF tracers43 has been performed.
In mice models for atherosclerosis, angiogenesis imaging
has been performed by NIRF using fluorescently labelled
antibodies targeting extra-domain B (ED-B), a molecule
that is also involved in angiogenesis.44
Apoptosis
Finally, apoptosis plays an important role as a feature of
complex human atherosclerotic plaques. The risk of plaque
rupture depends in part upon the presence of a necrotic
core, containing lipids, dead cells and debris with a thin
fibrous cap.45 Carotid artery plaques with an increased
necrotic core and a thin fibrous cap due to apoptosis of
macrophages or smooth muscle cells are known to be
instable and are at high risk for rupture.
Imaging of apoptosis in carotid artery plaques has
mainly been studied in animal models by targeting
markers of apoptosis such as annexin A5. In a rabbit
model, Technetium-99m labelled annexin A5 showed
a higher uptake in atherosclerotic lesions compared with
controls.46 In another rabbit study, Annexin A5 (111In-
labelled Annexin A5) was imaged in combination with MMP
activity (99mTc-labelled matrix metalloproteinase inhibitor
(MPI)) using SPECT-CT (Fig. 3).47 Annexin A5 and MPI
uptake were both visualised in atherosclerotic animals and
were interrelated.
In a clinical pilot study in four patients with a history of
TIA caused by symptomatic carotid artery stenosis, annexin
A5 uptake corresponded well with histopathological) activity and apoptosis by using 99mTc-labelled matrix metal-
clerosis. Micro-SPECT (top), and micro-SPECT-CT fusion images
ol diet using Tc-MPI (A) and In-AA5 (B). The left sets in A and B
hich reveal blood pool activity in the aorta (arrows) in front of
4 h after radiotracer administration. The radiotracer uptake in
rows). (With kind permission of A. Petrov, PhD, University of
Table 2 Molecular imaging in atherosclerosis.
Author (year) Molecular target Technique n Study subjects Results
Tawakol (2006) FDG PET 19 9 Atherosclerotic rabbits
10 Control rabbits
FDG uptake: atherosclerotic> control
Rudd (2002) FDG PET 8 8 Symptomatic carotid artery plaques (human),
contralateral side was used as control group
FDG uptake: symptomatic side> asymptomatic side
Davies (2005) FDG PET 12 12 Patients with carotid artery stenosis and symptoms High FDG uptake in 58% of target lesion, in 83%
in lesions corresponding with symptoms
Tawakol (2006) FDG PET 17 17 Carotid artery plaques (human) Correlation FDG uptake and CD68 expression
Graebe (2009) FDG PET 10 10 Symptomatic carotid artery plaques (human) Correlation FDG uptake and CD68 expression
Annovazzi (2006) IL-2 SPECT 23 14 Patients carotid artery stenosis
9 Patients carotid artery stenosis and statin treatment Correlation IL-2 uptake and IL-2Rþ cells
IL-2 uptake decreased after statin treatment
Ohtsuki (2001) MCP-1 Radiolabeled
autoradiography
10 Atherosclerotic rabbits MCP-1 uptake: atherosclerotic vessel wall> normal
vessel wall
Correlation MCP-1 uptake and macrophages
Chakrabarti (1995) AMA-MoAB Radiolabeled
autoradiography
8 4 Atherosclerotic rabbits
4 Control rabbits
AMA-MoAB uptake: atherosclerotic> controls
Jaffer (2006) Nano-particles NIRF
HR-MRI
11 Atherosclerotic mice, saline vs nanoparticles Plaque enhancement: nanoparticles> saline
Chen (2002) Cathepsin-B NIRF 20 10 ApoE/ mice
5 ApoE/eNOS/
5 Wildtype mice
Cathepsin-B enhancement: high in atherosclerotic
lesions compared to control mice
Deguchi (2006) MMP-2 MMP-9 NIRF 28 19 ApoE/ mice
9 ApoEþ/þ mice
MMP-2 and MMP-9 enhancement in aorta: ApoE/
> controls
Wallis de Vries (2009) MMP-9 NIRF 1 Symptomatic carotid artery plaque (human) MMP-signal corresponds with MMP-9 and MMP-2 values
Haider (2009) MPI
Annexin A5
SPECT 12 6 High-cholesterol diet rabbits
6 Control rabbits
Annexin A5 and MPI uptake: HC> controls
Correlation MPI and Annexin A5
Kolodgie (2003) Annexin A5 Radiolabelled
autoradiography
10 5 Atherosclerotic rabbits
5 Control rabbits
Annexin A5 uptake: atherosclerotic lesions>
normal arteries
Kietselaar (2004) Annexin A5 SPECT 4 2 Recently symptomatic carotid artery plaques (human)
2 Symptomatic carotid artery plaques >3
months earlier (human)
Annexin A5 uptake: recently symptoms>
not recently symptoms
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Advanced Carotid Plaque Imaging 131characterisation of vulnerability of the endarterectomy
specimens.48 Unstable plaques showed higher uptake of
annexin A5 while in stable plaques no uptake of annexin A5
was seen after SPECT imaging.
Although obviously more clinical studies in apoptotic
markers are needed, so far 99mTc-Annexin A5 is one of the
few tracers that have been used in the clinical setting of
acute vascular disease.
Thrombosis
In carotid artery plaques, thrombotic activity is associated
with stroke and TIAs.49 Unstable carotid artery plaques
express a wide array of thrombomodulatory factors and
expression of these factors is higher in unstable plaques
compared to stable plaques.50 In a large series of carotid
endarterectomy specimens, thrombotic activity was seen in
74% and 35% of patients with ischaemic stroke and TIAs,
respectively, and only in 14% of asymptomatic patients. In
stroke patients, thrombotic activity was seen until several
months after the first cerebrovascular event.49 These
findings suggest that thrombotic activity plays a crucial role
in plaque rupture and the pathogenesis of stroke.
HR-MRI has been used to identify thrombus formation
and intra-plaque haemorrhage in the carotid artery
plaque.51 MRI showed a sensitivity and specificity of 84%
in detecting complex plaques, defined as that with
surface rupture or intra-plaque haemorrhage.52 Other
studies have shown similar sensitivity and specificity
values (Table 2).53Table 3 The advantages and disadvantages of the various mole
Imaging technique Advantages
PET Non-invasive
Spatial resolution 2e3 times
better than SPECT
More specific than SPECT
Reproducible
Has been used in vivo in hum
SPECT Non-invasive
Has been used in vivo in hum
Better availability than PET
NIRF Non-invasive
No radio-activity
HR-MRI Non-invasive
No radio-activity
Has been used in vivo in hum
High spatial resolution
Identifies morphologic chara
HR-MRI using nanoparticles Non-invasive
No radio-activity
High spatial resolutionDiscussion and conclusion
Traditional imaging techniques for atherosclerosis focus
primarily on defining anatomic features of the atheroscle-
rotic plaque rather than pathophysiological processes.
However, the emerging knowledge of plaque biology
emphasises that other characteristics than the degree of
stenosis are important in risk assessment, namely stroke in
carotid artery disease.
Currently, we are entering a new era with the develop-
ment of state-of-the-art functional molecular imaging
techniques to identify cellular processes in vulnerable
carotid plaques. Radiographic scintigraphic techniques such
as PET and SPECT and fluorescent molecular imaging tech-
niques such as NIRF are the most promising techniques
currently available. Especially when functional molecular
imaging methods are combined with detailed anatomical
imaging by HR-MRI or CT and used in a multimodal setting,
these techniques seem to be able to accurately identify
processes in vulnerable carotid plaques. In addition, these
techniques may be useful for the evaluation of individual
therapeutic strategies and monitoring the effect of thera-
peutic interventions (Table 3).
Although the above-described approaches are prom-
ising, no large clinical prospective trials have been carried
out so far. Whereas multiple candidate targets have been
evaluated in preclinical molecular imaging studies, only
a few radionuclide or fluorescent targets have been
recently used in the clinical setting of carotid artery
stenosis. Additional research is needed, in part focussed oncular imaging techniques.
Disadvantages
ans
Radio-active probes
Partial volume effect
Target-to-background ratio
ans
Radio-active probes
Partial volume effect
Target-to-background ratio
Poor spatial resolution
Partial volume effect
Target-to-background ratio
Has only been used in animal
studies or ex vivo in carotid artery plaques
Poor spatial resolution
ans
cteristics
No information on molecular processes
Provides only information on inflammation
(macrophages)
Target-to-background ratio
Has only been used in animal studies
132 L. Hermus et al.the identification of additional and specific target mole-
cules of vulnerable carotid artery plaques and, on the other
hand, pharmacokinetic and toxicity testing prior to clinical
trials for validation of new imaging techniques.
In conclusion, it is clear that advanced molecular
imaging methods are an important development in
atherosclerotic research. The pathophysiological informa-
tion of plaque vulnerability that can be obtained by these
imaging techniques is of great potential for usage in clinical
practice and in future may improve the selection criteria
for vascular intervention. However, further research is
warranted before there will be clinical applicability.Conflict of interest
None.
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